Singapore markets closed

Sanofi (SNY)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
55.43+1.03 (+1.89%)
At close: 04:00PM EDT
55.67 +0.24 (+0.43%)
Pre-market: 07:54AM EDT
Full screen
Trade prices are not sourced from all markets
Previous close54.40
Bid55.76 x 1000
Ask55.88 x 800
Day's range54.81 - 55.88
52-week range46.93 - 58.10
Avg. volume2,219,124
Market cap138.426B
Beta (5Y monthly)0.36
PE ratio (TTM)19.80
EPS (TTM)2.80
Earnings dateN/A
Forward dividend & yield1.80 (3.30%)
Ex-dividend date26 May 2022
1y target est70.75
  • Zacks

    Top Stock Reports for Alphabet, UnitedHealth & Costco

    Today's Research Daily features new research reports on 16 major stocks, including Alphabet Inc. (GOOGL), UnitedHealth Group Incorporated (UNH), and Costco Wholesale Corporation (COST).

  • Zacks

    Sanofi, Regeneron's Dupixent Gets FDA Nod for 4th Indication

    The FDA approves Sanofi's (SNY) Dupixent for treating adults and children aged 12 and older with eosinophilic esophagitis, a chronic, progressive inflammatory disease.

  • Motley Fool

    This Safe Stock Is Dirt Cheap -- and It's Beating the Market

    The giant French drugmaker Sanofi (NASDAQ: SNY) isn't exactly an obvious candidate for a stock that's likely to beat the market, but its total return of around 8.5% this year is undoubtedly superior to the market's losses of more than 15.4%. Let's take a peek at Sanofi to appreciate why it could be a great pick for the more conservative portion of your holdings. Sanofi sells Dupixent, which treats atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyposis.